

This article was downloaded by:

On: 27 January 2011

Access details: *Access Details: Free Access*

Publisher *Taylor & Francis*

Informa Ltd Registered in England and Wales Registered Number: 1072954 Registered office: Mortimer House, 37-41 Mortimer Street, London W1T 3JH, UK



## Phosphorus, Sulfur, and Silicon and the Related Elements

Publication details, including instructions for authors and subscription information:

<http://www.informaworld.com/smpp/title~content=t713618290>

### Dapson in Heterocyclic Chemistry, Part I: Novel Synthesis of Sulfone Biscompounds for Antimicrobial and Antitumor Activities

M. M. Ghorab<sup>a</sup>; N. M. H. Taha<sup>b</sup>; M. A. A. Radwan<sup>c</sup>; N. E. Amin<sup>a</sup>; M. A. Shehab<sup>b</sup>; I. M. I. Faker<sup>c</sup>

<sup>a</sup> Department of Drug Radiation Research, National Center for Radiation Research and Technology (NCRRT), Nasr City, Cairo, Egypt <sup>b</sup> Organic Chemistry Department, Faculty of Science for Girls, Al-Azhar University, Cairo, Egypt <sup>c</sup> Applied Organic Chemistry Department, National Research Center, Cairo, Egypt

**To cite this Article** Ghorab, M. M. , Taha, N. M. H. , Radwan, M. A. A. , Amin, N. E. , Shehab, M. A. and Faker, I. M. I.(2008) 'Dapson in Heterocyclic Chemistry, Part I: Novel Synthesis of Sulfone Biscompounds for Antimicrobial and Antitumor Activities', *Phosphorus, Sulfur, and Silicon and the Related Elements*, 183: 12, 2891 — 2905

**To link to this Article:** DOI: 10.1080/10426500802505408

**URL:** <http://dx.doi.org/10.1080/10426500802505408>

PLEASE SCROLL DOWN FOR ARTICLE

Full terms and conditions of use: <http://www.informaworld.com/terms-and-conditions-of-access.pdf>

This article may be used for research, teaching and private study purposes. Any substantial or systematic reproduction, re-distribution, re-selling, loan or sub-licensing, systematic supply or distribution in any form to anyone is expressly forbidden.

The publisher does not give any warranty express or implied or make any representation that the contents will be complete or accurate or up to date. The accuracy of any instructions, formulae and drug doses should be independently verified with primary sources. The publisher shall not be liable for any loss, actions, claims, proceedings, demand or costs or damages whatsoever or howsoever caused arising directly or indirectly in connection with or arising out of the use of this material.

## Dapson in Heterocyclic Chemistry, Part I: Novel Synthesis of Sulfone Biscompounds for Antimicrobial and Antitumor Activities

M. M. Ghorab,<sup>1</sup> N. M. H. Taha,<sup>2</sup> M. A. A. Radwan,<sup>3</sup>  
N. E. Amin,<sup>1</sup> M. A. Shehab,<sup>3</sup> and I. M. I. Faker<sup>3</sup>

<sup>1</sup>Department of Drug Radiation Research, National Center for Radiation Research and Technology (NCRRT), Nasr City, Cairo, Egypt

<sup>2</sup>Organic Chemistry Department, Faculty of Science for Girls, Al-Azhar University, Cairo, Egypt

<sup>3</sup>Applied Organic Chemistry Department, National Research Center, Cairo, Egypt

*This article describes the synthesis of some novel sulfone bis- compounds bearing the biologically active thioether **3–6**; thioureido **7, 8, 15, 16**; triazole **10, 11**; thiosemicarbazido **9, 12, 13**; and 1,3,4-thiadiazole **14, 17** moieties starting with 4,4'-diisothiocyanto-1,1-diphenylsulfone **2**. The structures of newly synthesized compounds were confirmed by elemental analysis, IR, <sup>1</sup>H-NMR and mass spectral data. Compound **3** was found to be the most active compound against Escherichia coli. Also, compound **15** acted as potent cytotoxic agent.*

**Keywords** Antimicrobial and antitumor agents; sulfone derivatives

## INTRODUCTION

Bisheterocyclic compounds are currently an important group of organic compounds that are used as bactericides,<sup>1</sup> fungicides,<sup>2,3</sup> antitumor agents,<sup>4</sup> and for their radioprotective effects.<sup>5</sup> In addition, sulfone derivatives are known to possess interesting biological properties that show antitumor<sup>6</sup> and antimicrobial<sup>7</sup> activities. In addition, several types of compounds containing thioether, thioreado, triazole, thiosemicarbazido, and 1,3,4-thiadiazole have been shown to possess antitumor and antimicrobial<sup>8–10</sup> properties. The interesting antitumor and antimicrobial properties of sulfone derivatives prompted us to

Received 30 September 2007; accepted 11 December 2007.

Address correspondence to M. M. Ghorab, Department of Drug Radiation Research, National Center for Radiation Research and Technology (NCRRT), P.O. Box 29, Nasr City, Cairo, Egypt. E-mail: mmsghorab@yahoo.com


investigate in some detail this relatively unexplored class of potential antitumor and antimicrobial agents. Here we report the synthesis of some biscompounds bearing sulfone groups with the above-mentioned biologically active moieties to evaluate their antitumor and antimicrobial activities.

## RESULTS AND DISCUSSION

Treatment of dapson **1** with thiophosgene at room temperature in the presence of dilute hydrochloric acid<sup>9</sup> furnished the corresponding 4,4'-diisothiocyanato-1,1-diphenylsulfone **2**. The IR spectrum of compound **2** showed the absence of (NH<sub>2</sub>) bands and presence of bands at 3090 cm<sup>-1</sup> (CH arom.), 2102 cm<sup>-1</sup> (NCS), 1318, and 1146 cm<sup>-1</sup> (SO<sub>2</sub>).

The reactivity of diisothiocyanate **2** toward some oxygen and nitrogen nucleophiles was investigated. The reaction of diisothiocyanate **2** with methanol, ethanol, propanol, and/or butanol yielded the corresponding thiocarbamate derivatives (**3–6**) (Scheme 1). The structure of compounds **3–6** was proved by analytical and spectral data.

The IR spectrum of compound **3** showed the absence of a N=C=S band and showed the presence of bands at 3278 cm<sup>-1</sup> (NH), 2944 cm<sup>-1</sup> (CH aliph.), 1360, 1146 cm<sup>-1</sup> (SO<sub>2</sub>), and 1288 cm<sup>-1</sup> (C=S). <sup>1</sup>H-NMR spectrum of (**3** in DMSO-d<sub>6</sub>) revealed signals at 3.9 [s, 3H, 2OCH<sub>3</sub>], 7.4–8.0 [m, 8H, Ar–H], and 11.4 [s, 2H, 2NH]. Mass spectrum of compound **3** showed a molecular ion peak *m/z* 396 (M<sup>+</sup>, 27.03%) with a base peak at 57 (100%), and other significant peaks appeared at 378 (40.54%), 243




**SCHEME 1**

(43.24%), 153 (35.14%), 94 (45.95%), and 78 (37.84%). The IR spectrum of compound **4** revealed bands at  $3252\text{ cm}^{-1}$  (NH),  $3040\text{ cm}^{-1}$  (CH arom.),  $2946, 2850\text{ cm}^{-1}$  (CH aliph.),  $1320, 1156\text{ cm}^{-1}$  ( $\text{SO}_2$ ), and  $1200\text{ cm}^{-1}$  (C=S).  $^1\text{H-NMR}$  spectrum of (**4** in  $\text{DMSO-d}_6$ ) showed signals at 1.39 [t, 6H,  $2\text{CH}_3$ ], 4.6 [q, 4H,  $2\text{CH}_2$ ], 7.6–8.0 [m, 8H, Ar-H], and 11.4 [s, 2H, 2NH]. Mass spectrum of compound **4** exhibited a molecular ion peak  $m/z$  at 424 ( $\text{M-CH}_3$ , 9.7%) with a base peak at 57 (100%), and other significant peaks appeared at 350 (92.9%), 317 (66.1%), 290 (60.7%), 182 (74.9%), 150 (59.5%), 108 (73.7%), 90 (46.9%), and 76 (26.1%). IR spectrum of **5** showed bands at  $3240\text{ cm}^{-1}$  (NH),  $3276\text{ cm}^{-1}$  (CH arom.),  $2970, 2840\text{ cm}^{-1}$  (CH aliph.),  $1337, 1186\text{ cm}^{-1}$  ( $\text{SO}_2$ ), and  $1289\text{ cm}^{-1}$  (C=S).  $^1\text{H-NMR}$  spectrum of (**5** in  $\text{DMSO-d}_6$ ) revealed signals at 0.9 [t, 6H,  $2\text{CH}_3$ ], 1.7 [m, 4H,  $2\text{CH}_2$ ], 4.4 [t, 4H,  $2\text{CH}_2\text{O}$ ], 7.5–8.0 [m, 8H, Ar-H], and 11.5 [s, 2H, 2NH]. IR spectrum of compound **6** exhibited bands at  $3278\text{ cm}^{-1}$  (NH),  $3100\text{ cm}^{-1}$  (CH arom.),  $2958, 2870\text{ cm}^{-1}$  (CH aliph.),  $1330, 1146\text{ cm}^{-1}$  ( $\text{SO}_2$ ), and  $1288\text{ cm}^{-1}$  (C=S).  $^1\text{H-NMR}$  spectrum of (**6** in  $\text{DMSO-d}_6$ ) exhibited signals at 0.9 [t, 6H,  $2\text{CH}_3$ ], 1.3, 1.7 [m, 8H,  $4\text{CH}_2$ ], 4.4 [t, 4H,  $2\text{OCH}_2$ ], 7.4–8.0 [m, 8H, Ar-H], and 11.4 [s, 2H, 2NH].

The novel thioureido derivatives **7** and **8** were synthesized when diisothiocyanate **2** was allowed to react with propylamine and/or butylamine as nitrogen nucleophile (Scheme 2).

The IR spectrum of compound **7** revealed bands at  $3240\text{ cm}^{-1}$  (NH),  $3064\text{ cm}^{-1}$  (CH arom.),  $2960, 2930, 2874\text{ cm}^{-1}$  (CH aliph.),  $1318, 1154\text{ cm}^{-1}$  ( $\text{SO}_2$ ), and  $1220\text{ cm}^{-1}$  (C=S).  $^1\text{H-NMR}$  spectrum of (**7** in  $\text{DMSO-d}_6$ ) showed signals at 0.9 [t, 10H,  $2\text{CH}_3 + 2\text{CH}_2\text{N}$ ], 1.5 [m, 4H,  $2\text{CH}_2$ ], 7.7, 7.9 [2d, 8H, Ar-H], and 9.9 [s, 2H, 2NH]. Mass spectrum of compound **7** revealed a molecular ion peak  $m/z$  at 450 ( $\text{M}^+$ , 75%), with a base peak at 291 (100%), and other significant peaks appeared at 324 (75%), 268 (68.75%), and 77 (75%). The IR spectrum of compound **8** revealed bands



**SCHEME 2**


at 3246  $\text{cm}^{-1}$  (NH), 3062  $\text{cm}^{-1}$  (CH arom.), 2958, 2930, 2872  $\text{cm}^{-1}$  (CH aliph.), 1320, 1152  $\text{cm}^{-1}$  ( $\text{SO}_2$ ), and 1250  $\text{cm}^{-1}$  (C=S).  $^1\text{H}$ -NMR spectrum of (**8** in  $\text{DMSO}-d_6$ ) exhibited signals at 0.8 [t, 6H,  $2\text{CH}_3$ ], 1.3 [q, 4H,  $2\text{CH}_2\text{NH}$ , 1.4–1.5 [m, 8H,  $4\text{CH}_2$ ], 7.5–7.9 [2d, 8H, AB system], and 9.9 [s, 2H, 2NH]. Mass spectrum of compound **8** showed a molecular ion peak  $m/z$  at 478 ( $\text{M}^+$ , 0.2%), with a base peak at 332 (100%), and other significant peaks appeared at 477 ( $\text{M}-1$ , 0.5%), 446 (0.86%), 371 (4.19%), 290 (19.16%), 268 (3.24%), 182 (36.48%), 150 (15.64%), 134 (26.27%), 90 (3.67%), and 76 (0.19%).

It is observed from the literature that the thiosemicarbazide moiety plays a vital role in many biological activities, such as antibacterial<sup>11</sup> antitumor<sup>12</sup> activities. Thus treatment of diisothiocyanate **2** with hydrazine hydrate in ethanol at room temperature afforded the corresponding thiosemicarbazide derivative **9** (Scheme 2).

The IR spectrum of **9** revealed bands at 3372, 3278  $\text{cm}^{-1}$  (NH,  $\text{NH}_2$ ), 2926  $\text{cm}^{-1}$  (CH aliph.), 1382, 1174  $\text{cm}^{-1}$  ( $\text{SO}_2$ ), and 1224  $\text{cm}^{-1}$  (C=S). Mass spectrum of compound **9** exhibited a molecular ion peak  $m/z$  at 396 ( $\text{M}^+$ , 0.50%), 395 ( $\text{M}-1$ , 0.84%) with a base peak at 108 (100%), and other significant peaks appeared at 368 (8.76%), 313 (8.88%), 285 (5.51%), 248 (80.24%), 184 (10.33%), 140 (62.55%), 118 (8.18%), and 55 (71.08%).

1,2,4-triazole derivatives **10**, **11** were obtained via a reaction of compound **2** with thiosemicarbazide and/or thiocarbohydrazide. The reaction progress was followed easily by testing for the evolution of hydrogen sulfide (lead acetate paper) (Scheme 3).

The IR spectrum of compound **10** revealed bands at 3436, 3352, 3225  $\text{cm}^{-1}$  (NH,  $\text{NH}_2$ ), 1630  $\text{cm}^{-1}$  (C=N), 1328, and 1142  $\text{cm}^{-1}$  ( $\text{SO}_2$ ).




SCHEME 3

Mass spectrum of compound **10** revealed a molecular ion peak  $m/z$  at 446 ( $M^+$ , 0.46%), with a base peak at 78 (100%), and other significant peaks appeared at 381 (7.30%), 347 (8.11%), 290 (0.66%), 248 (48.82%), 192 (15.05%), 188 (0.88%), 140 (24.82%), 108 (34.84%), 92 (18.88%), and 77 (5.20%). The IR spectrum of compound **11** showed bands at 3450, 3368, 3200  $\text{cm}^{-1}$  (NH,  $\text{NH}_2$ ), 1630,  $\text{cm}^{-1}$  ( $\text{C}=\text{N}$ ), 1408, 1146  $\text{cm}^{-1}$  ( $\text{SO}_2$ ), and 1290  $\text{cm}^{-1}$  ( $\text{C}=\text{S}$ ). Mass spectrum of compound **11** revealed a molecular ion peak  $m/z$  at 476 ( $M^+$ , 0.87%), with a base peak at 78 (100%), and other significant peaks appeared at 382 (0.78%), 332 (4.63%), 276 (8.38%), 248 (8.55%), 160 (20.11%), 108 (35.06%), and 77 (9.85%).


When compound **2** was allowed to react with phenyl hydrazine and/or benzoyl hydrazine, the thiosemicarbazide derivatives **12** and **13** were obtained (Scheme 4).

The IR spectrum of compound **12** revealed bands 3234, 3200  $\text{cm}^{-1}$  (NH), 2924  $\text{cm}^{-1}$  (CH aliph.), 1300, 1148  $\text{cm}^{-1}$  ( $\text{SO}_2$ ), and 1274  $\text{cm}^{-1}$  ( $\text{C}=\text{S}$ ).  $^1\text{H}$ -NMR spectrum of compound (**12** in  $\text{DMSO}-d_6$ ) showed signals at 6.8–7.9 [m, 18H, Ar-H], 8.3, 10.1, and 10.3 [s, 6H, 6NH]. Mass spectrum of compound **12** revealed a molecular ion peak  $m/z$  at 548 ( $M^+$ , 5.58%), with a base peak at 66 (100%), and other significant peaks appeared at 549 ( $M+1$ , 1.72%), 496 (5.04%), 438 (6.31%), 342 (10.04%), 250 (32.94%), 218 (38.13%), 156 (10.74%), and 78 (67.78%).

The IR spectrum of **13** showed bands at 3348, 3250  $\text{cm}^{-1}$  (NH), 3100  $\text{cm}^{-1}$  (CH arom.), 2926  $\text{cm}^{-1}$  (CH aliph.), 1726  $\text{cm}^{-1}$  ( $\text{C}=\text{O}$ ), 1390, 1146  $\text{cm}^{-1}$  ( $\text{SO}_2$ ), and 1290  $\text{cm}^{-1}$  ( $\text{C}=\text{S}$ ). Mass spectrum of compound **13** revealed a molecular ion peak  $m/z$  at 604 ( $M^+$ , 1.87%), with a base



SCHEME 4



SCHEME 5

peak at 248 (100%), and other significant peaks appeared at 605 ( $M+1$ , 1.71%), 603 ( $M-1$ , 4.10%), 578 (12.10%), 552 (8.22%), 368 (38.10%), 313 (1.25%), 178 (22.38%), 108 (83.81%), and 78 (3.20%).


We also investigated the reactivity of compound **9** toward acid. Thus, compound **9** was reacted with formic acid to produce the corresponding the 1,3,4-thiadiazole derivative **14** (Scheme 5).

The IR spectrum of compound **14** exhibited absorption bands at 3370  $\text{cm}^{-1}$  (NH), 1592  $\text{cm}^{-1}$  (C=N), 1310, and 1146  $\text{cm}^{-1}$  ( $\text{SO}_2$ ).  $^1\text{H}$ -NMR spectrum of compound (**14** in  $\text{DMSO-d}_6$ ) revealed signals at 7.7–8.0 [m, 8H, Ar-H], 9.0 [s, 2H, 2NH], and 11.0 [s, 2H, 2N=CH]. Mass spectrum of compound **14** exhibited a molecular ion peak  $m/z$  at 416 ( $M^+$ , 1.15%), with a base peak at 108 (100%), and other significant peaks appeared at 417 ( $M+1$ , 0.38%), 418 ( $M+2$ , 0.23%), 374 (5.73%), 332 (47.78%), 290 (13.07%), 276 (31.18%), 192 (10.08%), 141 (12.08%), 90 (12.88%), and 59 (81.88%).


Also, when diisothiocyanate derivative **2** was treated with glycine as another nucleophile, the corresponding 4,4'-bis(3-carboxymethylthioureido)-1,1'-diphenylsulfone was obtained. The structure of **15** was proved on the basis of elemental analyses as well as spectroscopic data (Scheme 6).

The IR spectrum of **15** revealed bands at 3422  $\text{cm}^{-1}$  (br, NH, OH), 1720  $\text{cm}^{-1}$  (C=O), 1314, 1150  $\text{cm}^{-1}$  ( $\text{SO}_2$ ), and 1250  $\text{cm}^{-1}$  (C=S).  $^1\text{H}$ -NMR spectrum of (**15** in  $\text{DMSO-d}_6$ ) exhibited signals at 6.7 [d, 4H, 2CH<sub>2</sub>], 7.4–8.0 [m, 8H, Ar-H], 10.0 [s, 2H, 2NH], 10.9 [s, 2H, 2OH].

Finally, the Schiff's base **16** was achieved by condensing compound **9** with benzaldehyde in ethanol under reflux, while the cyclic compound



SCHEME 6



SCHEME 7

**17** was obtained via reaction of **9** with benzaldehyde in acetic acid in presence of fused sodium acetate (Scheme 7).


The IR spectrum of **16** showed bands at  $3306\text{ cm}^{-1}$  (NH),  $1592\text{ cm}^{-1}$  (C=N),  $1320, 1148\text{ cm}^{-1}$  ( $\text{SO}_2$ ), and  $1280\text{ cm}^{-1}$  (C=S). Mass spectrum of **16** revealed a molecular ion peak  $m/z$  573 ( $M+1$ , 6.04%) with a base peak at 77 (100%). IR spectrum of compound **17** exhibited bands at  $3234\text{ cm}^{-1}$  (NH),  $1594\text{ cm}^{-1}$  (C=N),  $1326$ , and  $1144\text{ cm}^{-1}$  ( $\text{SO}_2$ ). Mass spectrum of compound **17** showed a molecular ion peak  $m/z$  572 ( $M^+$ , 13.24%) with a base peak at 52 (100%) (Chart 1).

## Antimicrobial Activity

Some of the newly synthesized compounds were screened for their antimicrobial activity using the diffusion agar technique.<sup>13</sup> The tested compounds were dissolved in *N,N*-dimethylformamide (DMF), which showed no inhibition zones. Tables 1 and 2 list the screening results of the tested compounds against the Gram-negative bacteria *Escherichia coli* and *Salmonella typhi*, Gram-positive bacteria *Staphylococcus aureus* and *Bacillus subtilis*, and pathogenic fungi *Aspergillus niger* and *Aspergillus flavus*. The reference antibiotic chloramphenicol and fungicide Grisoflavin were used as positive controls for comparison. The fungi cultures were maintained on Czapek's Dox agar media.

Diphenylsulfone bearing thiocarbamic acid *o*-methyl ester **3** was found to be the most active compound against Gram-negative bacteria *Escherichia coli*. The results indicated that the biologically active compound **3** was almost as potent as the standard antibiotic chloramphenicol as positive control.



**SCHEME** Mass fragmentation pattern of compound **17**.

**TABLE I Antibacterial Activity of Some Synthesized Compounds**

Compd No.	<i>E. coli</i>			<i>Salmonella typhi</i>			<i>Staphylococcus aureus</i>			<i>Bacillus subtilus</i>		
	1	2.5	5	1	2.5	5	1	2.5	5	1	2.5	5
<b>2</b>	++	++	++	+	+	+	+	++	++	+	++	++
<b>3</b>	++	+++	+++	+	+	++	+	+	+	++	++	+++
<b>7</b>	0	+	+	0	0	+	0	0	0	+	+	+
<b>10</b>	++	++	++	+	+	++	+	++	+	0	+	+
<b>12</b>	+	++	++	++	++	++	++	++	++	+	+	++
<b>16</b>	++	++	++	0	0	+	0	0	0	+	++	++
<b>DMF</b>	0	0	0	0	0	0	0	0	0	0	0	0
<b>Chloramphenicol</b>	++	+++	+++	+++	+++	+++	++	++	+++	++	+++	+++

Well diameter 1 cm (100 mL of each conc. was tested).

Inhibition values = 0.1–0.5 cm beyond control = +

Inhibition values = 0.6–0.1 cm beyond control = ++

Inhibition values = 1.1–1.5 cm beyond control = +++

Inhibition values = > 1 cm beyond control = +++++, 0 = not detected.

## Antitumor Activity (In Vitro Study)

### Reagents

- 1) RPMI 1640 medium (sigma).
- 2) Ehrlich Ascites Carcinoma cells (EAC) suspension ( $2.5 \times 10^5$  mL).

**TABLE II Antifungal Activity of Some Synthesized Compounds**

Compd. No.	<i>Aspergillusniger</i>			<i>Aspergillus vlavus</i>		
	1	2.5	5	1	2.5	5
<b>2</b>	+	+	++	+	+	+
<b>3</b>	+	++	++	+	+	++
<b>7</b>	0	0	+	0	0	+
<b>10</b>	+	+	++	+	++	++
<b>12</b>	+	++	++	++	++	++
<b>16</b>	+	+	+	+	+	++
<b>DMF</b>	0	0	0	0	0	0
<b>Grisofluvine</b>	+++	+++	+++	+++	+++	+++

Well diameter 1 cm (100 mL of each conc. was tested).

Inhibition values = 0.1–0.5 cm beyond control = +

Inhibition values = 0.6–0.1 cm beyond control = ++

Inhibition values = 1.1–1.5 cm beyond control = +++

Inhibition values = > 1 cm beyond control = +++++, 0 = not detected.

- 3) Trypan blue dye: A stock solution was prepared by dissolving 1 g of the dye in distilled water (100 mL). The working solution was then prepared by diluting 1 mL of the stock solution with 9 mL of distilled water. The stain was used then for staining the dead EAC cells.
- 4) The compounds tested were (**2–15**).

### Procedure

- 1) EAC cells were obtained by needle aspiration of the ascetic fluid from preinoculated mice under aseptic conditions.<sup>14</sup>
- 2) The cells were tested for viability and contamination by staining a certain cell volume of this fluid with an equal volume of the working solution of trypan blue dye.<sup>15,16</sup>
- 3) The ascetic fluid was diluted with saline (1:10) to contain  $2.5 \times 10^6$  mL cells on a hemocytometer.
- 4) In a set of sterile test tubes, 0.1 mL of tumor cells suspension, 0.8 mL RPMI 1640 media, and 0.1 mL of each tested compound (corresponding to 100, 50, and 25  $\mu\text{g/mL}$ ) were mixed. The test tubes were incubated at 37°C for 2 hr. A trypan blue exclusion test<sup>15,16</sup> was carried out to calculate the presence of nonviable cells. Compounds producing more than 70% nonviable cells are considered active.<sup>16</sup>

$$\% \text{ of non-viable cells} = \frac{\text{No. of non viable}}{\text{Total No. of cells}} \times 100 \quad (1)$$

The relationship between surviving fraction and drug concentration was plotted to obtain the survival curve of EAC cells. The response parameter calculated was the  $\text{IC}_{50}$  value, which corresponds to the compound concentration causing 50% mortality in net cells (Table 3).

The results indicated that biologically active compound **15** was almost more active than the reference drug (Doxorubicin). From these results it was found that diphenylsulfone having carboxymethylthioureido moiety **15** exhibited nonviable cells of about 90% at a concentration of 50  $\mu\text{g/mL}$ .

### EXPERIMENTAL

Melting points were uncorrected. IR spectra were recorded (KBr) on a Perkin Elmer 1650 spectrophotometer.  $^1\text{H-NMR}$  spectra were recorded on varian Gemini spectrometer 200 (200 MHz) using  $\text{DMSO-d}_6$  as a solvent, and TMS as internal standard chemical shifts were expressed as  $\delta$  ppm units. Mass spectra were recorded on a gas chromatography

**TABLE III In Vitro Antitumor Activity of Some Newly Synthesized Compounds**

Compound No.	Non-viable cells (%) Concentration ( $\mu\text{g/mL}$ )			$\text{IC}_{50}^a$
	100	50	25	
2	0	0	0	>100
4	20	10	0	>100
7	10	0	0	>100
8	20	0	0	>100
9	0	0	0	>100
11	0	0	0	>100
14	20	10	0	>100
15	100	90	85	0.5
Doxorubicin	100	55	20	52

$a\text{IC}_{50} > 100 \text{ Mg/mL}$  is considered to be inactive.

GC-MS 9p 100 Ex (schiumadzu instrument) at 70 ev. Microanalytical data were obtained from the Microanalytical Data Unit at Cairo University.

#### 4,4'-Diisothiocyanato-1,1'-diphenylsulfone (2)

Dapson **1** (0.01 mol) was dissolved in 200 mL of  $\text{H}_2\text{O}$  containing 50 mL concentrated HCl. To this 0.02 mol of  $\text{CSCl}_2$  was added in one portion. Stirring began immediately and continued until all of the red color of  $\text{CSCl}_2$  had disappeared (1 hr) and the product was precipitate as white crystals. The resulting precipitate was filtered off, dried, and recrystallized from acetone to give (**2**, Table 4).

#### 4,4'-Bis[thiocarbamic acid-O-methyl ester]-1,1'-diphenylsulfone (**3**), 4,4'-Bis[thiocarbamic acid-O-ethyl ester]-1,1'-diphenylsulfone (**4**), 4,4'-bis[thiocarbamic acid-O-propylester]-1,1'-diphenylsulfone (**5**), and 4,4'-Bis[thiocarbamic acid-O-butyl ester]-1,1'-diphenylsulfone (**6**)

A solution of **2** (0.01 mol) in alcohol (methyl, ethyl, propyl, butyl) (20 mL) was refluxed for 8 hr. The solid obtained was recrystallized from dioxane to give (**3–6**), respectively (Table 4).

TABLE IV Physical and Analytical Data of the Newly Synthesized Compounds

Compound	m.p [°C]	Yield [%]	Mol. Formula (Mol. Wt)	Analyses % Required/Found			
				C	H	N	S
<b>2</b>	145–47	88	C <sub>14</sub> H <sub>8</sub> N <sub>2</sub> O <sub>2</sub> S <sub>3</sub> (332)	50.60 50.40	2.40 2.70	8.43 8.70	28.91 29.20
<b>3</b>	150–152	75	C <sub>16</sub> H <sub>16</sub> N <sub>2</sub> O <sub>4</sub> S <sub>3</sub> (396)	48.48 48.60	4.04 4.30	7.07 7.20	24.24 24.50
<b>4</b>	214–215	78	C <sub>18</sub> H <sub>20</sub> N <sub>2</sub> O <sub>4</sub> S <sub>3</sub> (424)	50.94 51.20	4.71 4.40	6.60 6.80	22.64 22.90
<b>5</b>	198–200	76	C <sub>20</sub> H <sub>24</sub> N <sub>2</sub> O <sub>4</sub> S <sub>3</sub> (452)	53.09 53.00	5.31 5.40	6.19 6.10	21.24 21.50
<b>6</b>	169–170	74	C <sub>22</sub> H <sub>28</sub> N <sub>2</sub> O <sub>4</sub> S <sub>3</sub> (480)	55.00 54.80	5.83 5.50	5.83 5.60	20.00 19.70
<b>7</b>	175–177	81	C <sub>20</sub> H <sub>26</sub> N <sub>4</sub> O <sub>3</sub> S <sub>3</sub> (450)	53.33 53.20	5.78 5.50	12.44 12.10	21.33 21.60
<b>8</b>	185–187	74	C <sub>22</sub> H <sub>30</sub> N <sub>4</sub> O <sub>2</sub> S <sub>3</sub> (478)	55.23 55.50	6.28 6.50	11.71 11.40	20.08 20.30
<b>9</b>	161–163	86	C <sub>14</sub> H <sub>16</sub> N <sub>6</sub> O <sub>2</sub> S <sub>3</sub> (396)	42.42 42.10	4.04 4.30	21.21 21.50	24.24 24.50
<b>10</b>	260–262	82	C <sub>16</sub> H <sub>14</sub> N <sub>8</sub> O <sub>3</sub> S <sub>3</sub> (446)	43.05 43.30	3.14 3.40	25.11 25.40	21.52 21.80
<b>11</b>	208–210	79	C <sub>16</sub> H <sub>16</sub> N <sub>10</sub> O <sub>2</sub> S <sub>3</sub> (476)	40.33 40.70	3.36 3.10	29.41 29.70	20.17 20.40
<b>12</b>	165–167	71	C <sub>26</sub> H <sub>24</sub> N <sub>6</sub> O <sub>2</sub> S <sub>3</sub> (548)	56.93 56.70	4.38 4.10	15.32 15.60	17.51 17.80
<b>13</b>	240–242	69	C <sub>28</sub> H <sub>24</sub> N <sub>6</sub> O <sub>4</sub> S <sub>3</sub> (604)	55.63 55.80	3.97 3.70	13.91 14.20	15.89 15.50
<b>14</b>	268–270	72	C <sub>16</sub> H <sub>12</sub> N <sub>6</sub> O <sub>2</sub> S <sub>3</sub> (416)	46.15 46.50	2.88 3.20	20.19 20.40	23.08 23.40
<b>15</b>	195–197	81	C <sub>18</sub> H <sub>18</sub> N <sub>4</sub> O <sub>6</sub> S <sub>3</sub> (482)	44.81 44.50	3.73 3.40	11.62 11.40	19.92 19.60
<b>16</b>	83–85	80	C <sub>28</sub> H <sub>24</sub> N <sub>6</sub> O <sub>3</sub> S <sub>3</sub> (572)	58.74 58.90	4.20 4.50	14.68 14.50	16.78 16.90
<b>17</b>	260–262	78	C <sub>28</sub> H <sub>24</sub> N <sub>6</sub> O <sub>2</sub> S <sub>3</sub> (572)	58.74 58.90	4.20 4.50	14.68 14.40	16.78 16.30

**4,4'-Bis(3-propyl-2-thioxo)-1,1'-diphenylsulfone (7) and 4,4'-bis(3-butyl-2-thioxo)-1,1'-diphenylsulfone(8)**

A mixture of **2** (0.01 mol) and propylamine and/or butyl amine (0.02 mol) in dioxane (30 mL) containing few drops of triethylamine was refluxed for 6 hr. The solid that formed upon heating was recrystallized from dioxane to give (**7**, **8**), respectively (Table 4).

**4,4'-Bis(thiosemicarbazid-4-yl)-1,1'-diphenylsulfone(9)**

A solution of **2** (0.01 mol) and hydrazine hydrate (0.02 mol) in ethanol (30 mL) was stirred for 3 hr. The solid that formed was collected and recrystallized from ethanol to give (**9**), (Table 4).

**4,4'-Bis(5-amino-3-thioxo-2,4-dihydro,1,2,4-triazol-4-yl)-1,1'-diphenylsulfone **10** and 4,4'-Bis[1-(5-mercapto-4-amino)-4H-1,2,4-triazolo-3-yl]thiosemicarbazid-4-yl)-1,1'-diphenylsulfone(**11**)**

A mixture of **2** (0.01 mol) and thiosemicarbazide and/or thiocarbohydrazide (0.02 mol) in ethanol (30 mL) containing a few drops of triethylamine was refluxed until evolution of hydrogen sulfide had stopped (8 hr). The solid product was collected and recrystallized from ethanol to give (**10**, **11**), respectively (Table 4).

**4,4'-Bis(phenylthiosemicarbazide-4-yl)-1,1'-diphenylsulfone (**12**) and 4,4'-Bis(benzoylthiosemicarbazide-4-yl)-1,1'-diphenylsulfone(**13**)**

A solution of **2** (0.01 mol) and phenyl hydrazine and/or benzoyl hydrazine (0.02 mol) in dioxane (30 mL) was refluxed for 3 hr. The solid obtained was recrystallized from acetic acid to give (**12**) and (**13**), respectively (Table 4).

**4,4'-Bis(1,3,4-thiadiazolylamino)-1,1'-diphenylsulfone (**14**)**

A solution of compound **9** (0.01 mol) in formic acid (20 mL) was heated under reflux for 4 hr. After cooling, the precipitate was filtered off and recrystallized from dioxane to give (**14**) (Table 4).

**4,4'-Bis(3-carboxymethyl-thioureido)-1,1'-diphenylsulfone (15)**

A mixture of **2** (0.01 mol) and glycine (0.02 mol) in dioxane (30 mL) containing 3 drops of triethylamine was refluxed for 6 hr. The obtained solid was recrystallized from dioxane to give **(15)** (Table 4).

**4,4'-Bis(1-benzylidene-thiosemicarbazide-4-yl)-1,1'-diphenylsulfone (16)**

A mixture of **9** (0.01 mol) and benzaldehyde (0.02 mol) in ethanol (50 mL) was refluxed for 5 hr. The obtained solid was recrystallized from ethanol to give **(16)** (Table 4).

**4,4'-Bis[(5-phenyl-4,5-dihydro[1,3,4]thiadiazol-2-yl)amino]-1,1'-diphenylsulfone (17)**

A mixture of **9** (0.01 mol) and benzaldehyde (0.02 mol) in acetic acid (30 mL) containing 1 g fused sodium acetate was refluxed for 10 hr. The reaction mixture was poured into ice water. The obtained solid was recrystallized from dimethylformamide/ethanol to give **(17)** (Table 4).

**REFERENCES**

- [1] N. C. Desai, *Indian J. Chem. Sect. B*, **32**, 343 (1993).
- [2] M. M. Ghorab, A. M. Sh. El-Sharief, Y. A. Ammar, and Sh. I. Mohamed, *Il Farmaco*, **55**, 354–361 (2000).
- [3] M. Sharma and M. Tomasz, *Chem. Res. Toxicol.*, **7**[3], 390–400 (1994).
- [4] S. N. Maiti, D. P. Czajkowski, N. A. V. Reddy, P. S. J. Kateta, and R. G. Micetich, *Bioorganic & Medicinal Chemistry Letters*, **6**,(7) 823–826 (1996).
- [5] M. M. Ghorab, O. M. Nassar, and A. Y. Hassan, *Phosphorus, Sulfur, and Silicon*, **134/135**, 57–76 (1998).
- [6] L. Garuti, M. Roberti, and E. De. Clercq, *Bioor. Med. Chem. Lett.*, **12**,(19), 2707–2710 (2002).
- [7] M. M. Ghorab, H. I. Heiba, and N. E. Amin, *Acta Pharm.*, **50**, 131–139 (2000).
- [8] M. M. Ghorab, S. G. Abdel-Hamide, and S. M. El-Sayed, *Phosphorus, Sulfur, and Silicon*, **142**, 57–68 (1998).
- [9] H. I. Heiba, M. M. Ghorab, N. E. Amin, and L. Ramadan, *Egypt. J. Biotechnol.*, **4**, 16–30 (1998).
- [10] M. M. Ghorab, S. G. Abdel-Hamide, M. S. A. El-Gaby, and S. M. El-Sayed, *Acta Pharm.*, **49**, 1–10 (1999).
- [11] B. G. Bennis, B. A. Gingras, and C. H. Bayley, *Appl. Microbiol.*, **8**, 353 (1960).
- [12] D. M. Wiles, B. A. Gingras, and T. Suprumchuk, *Can. J. Chem.*, **45**, 1735 (1967).

- [13] L. P. Carrod and F. D. Grady, *Antibiotic and Chemotherapy*, 3rd Ed., Churchill Livingstone, Edinburgh, UK, p. 477(1972).
- [14] M. M. El-Merzabani, A. A. ElAaser, and M. A. Attia, *J. Planta Medica*, **36**, 150 (1972).
- [15] H. Lazarus, M. Targela, H. Mazzone, J. Lepoy, B. Boone, and G. Foley, *Cancer Chemotherapy*, **50**, 543 (1966).
- [16] D. J. Takamoto, C. Dunfoed, and M. M. McMuiray, *Toxicon.*, **20**, 293 (1982).